36 results about "Subunit gene" patented technology

The invention relates to a group of specific amplification primers for mitochondrial genes of procambarus clarkia and application thereof, and belongs to the technical field of molecular biology, and the mitochondrial genes of the procambarus clarkia comprise cytochrome c oxidase I subunit genes and cytochrome b genes. The specific amplification primer of the CO I gene comprises a CO I gene upstream primer and a CO I gene downstream primer, wherein the base sequences of the CO I gene upstream primer and the CO I gene downstream primer are respectively shown as SEQ NO.1 and SEQ NO.2; the specific amplification primer of the Cytb gene comprises a Cytb gene upstream primer and a Cytb gene downstream primer of which the base sequences are respectively as shown in SEQ NO.3 and SEQ NO.4. The invention further discloses a kit for detecting the Cytb gene. According to the amplification method of the mitochondrial gene of the procambarus clarkia, PCR (Polymerase Chain Reaction) amplification is carried out on a DNA (Deoxyribonucleic Acid) template solution of the procambarus clarkia by adopting amplification primers of a mitochondrial COI gene and a Cytb gene of the procambarus clarkia. The procambarus clarkia mitochondrial gene specific amplification primer has high specificity, a single target gene can be stably amplified, the length of the obtained procambarus clarkia mitochondrial COI gene segment reaches about 1000 bp, and the length of the obtained procambarus clarkia mitochondrial Cytb gene segment reaches about 800 bp.

Provided are a theanine-producing strain and use thereof in tea fermentation production. A corynebacterium glutamicum is proposed, which includes an alanine decarboxylase CsAlaDC mutant. The theanine-producing strain is obtained by taking the corynebacterium glutamicum as a starting strain, knocking out in sequence an α-ketoglutarate dehydrogenase E1 subunit gene odhA, a glutamate external transporter gene Ncg11221 and a lactate dehydrogenase gene ldh; and / or expressesing a citrate synthase gene gltA, a pyruvate kinase gene pyk and a glutamate dehydrogenase gene gdh; and / or overexpressing an alanine dehydrogenase alaA and integrating a γ-glutamine synthetase GMAS into a cg1960 pseudogene locus of the corynebacterium glutamicum.

The invention discloses a nuclear factor YB subunit gene GhNF-YB3 and application thereof. The nucleotide sequence of the gene GhNF-YB3 is shown as SEQ ID NO. 1, and the nucleotide sequence of the gene GhNF-YB3 is shown as SEQ ID NO. The site gene GhNF-YB3 significantly related to the cotton yield trait is obtained by performing yield trait investigation on 245 upland cotton varieties and combining population genome re-sequencing and ovule transcriptome sequencing one day after flowering to perform GWAS and eQTL positioning. Gene expression of the gene GhNF-YB3 is in significant positive correlation with two yield traits, namely seed index and boll weight, and the gene GhNF-YB3 may be a causal gene for regulating and controlling the traits of the seed index of cotton. The nuclear factor YB subunit gene GhNF-YB3 disclosed by the invention can be applied to identification of high-yield upland cotton varieties and improvement of cotton yield traits.

The present disclosure relates to RNAi agents, e.g., double-stranded RNAi agents, e.g., siRNAs, capable of inhibiting expression of the subunit beta E (INHBE) gene. Also disclosed are pharmaceutical compositions comprising the INHBE RNAi agents, and methods of use thereof. The INHBE RNAi agents disclosed herein can be conjugated to targeting ligands to facilitate delivery to cells, including to hepatocytes. Delivery of the INHBE RNAi agent in vivo results in inhibition of expression of the INHBE gene. RNAi agents may be used in methods of treating diseases, disorders, or conditions mediated in part by the expression of the INHBE gene, such as obesity, diabetes, liver inflammation, dyslipidemia, or metabolic diseases.

The application discloses a nuclear factor YB subunit gene GhNF-YB3 and application thereof, the nucleotide sequence of the gene GhNF-YB3 is shown as SEQ ID NO. 1; through yield character investigation on 245 upland cotton varieties, GWAS and eQTL positioning are carried out in combination with population genome resequencing and ovule transcriptome sequencing one day after flowering, and a site gene GhNF-YB3 significantly related to cotton yield character is obtained. The gene expression of the gene GhNF-YB3 is significantly positively correlated with two yield characters of seed index and boll weight, and the gene may be a causal gene for regulating cotton seed index character. The nuclear factor YB subunit gene GhNF-YB3 of the application can be applied to identification of high-yield upland cotton varieties and improvement of cotton yield character.

The present disclosure provides human inhibin subunit beta E (INHBE) gene-targeting double stranded oligonucleotides, compositions, and methods of using the same, either alone or in combination with additional therapeutics, for preventing and / or treating various INHBE-related disorders, including maintenance of weight loss achieved. In some embodiments, the provided double stranded oligonucleotides comprise certain chemistry modifications, e.g., stereospecific internucleotidic linkage modifications, and have unexpected advantageous properties.

The present invention relates to therapeutic compounds, novel RNA interference (RNAi) agents that reduce the expression of a voltage gated sodium channel alpha subunit 10 (SCN10A) gene encoding a Nav 1.8 or a subunit of the Nav 1.8 sodium channel. Such RNAi agents reduce the level of the intact Nav 1.8 sodium channel and are useful in the treatment of diseases involving regulation of SCN10A expression and function, such as chronic pain.

The disclosure relates to double-stranded ribonucleic acid (dsRNA) targeting an INHBE gene, and methods of using the dsRNA to inhibit expression of INHBE.

The invention belongs to the technical field of gene engineering, and discloses a method for synthesizing L-cysteine through whole-cell catalysis, recombinant Escherichia coli and application, and the recombinant Escherichia coli is constructed through the following method: knocking out sdaA and tdcG genes for coding L-serine dehydratase; mutant beta subunit genes are obtained to construct recombinant plasmids, and the recombinant plasmids efficiently overexpress mutant genes and genes trpA in strains to obtain recombinant escherichia coli. The method is mild in reaction condition, low in energy consumption, environmentally friendly and high in substrate utilization rate through an enzyme method, and the overall cost is obviously reduced. The catalytic system can efficiently react at 25-35 DEG C from neutral to alkalescence, high temperature and high pressure or toxic chemical reagents are not needed, and energy consumption and environmental pressure are remarkably reduced. Meanwhile, the reaction system is high in substrate conversion rate and few in side reaction, the utilization rate of raw materials is greatly increased, and the method has obvious economic advantages.

A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mIl2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG / Il2rg KO / hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g., S. typhi or M. tuberculosis is described. A mouse that models a human pathogen infection that is poorly modeled in mice is described, e.g., a mouse that models a human mycobacterial infection, wherein the mouse develops one or more granulomas comprising human immune cells. A mouse that comprises a human hematopoietic malignancy that originates from an early human hematopoietic cells is described, e.g., a myeloid leukemia or a myeloproliferative neoplasia.

This invention belongs to the field of agricultural biotechnology and discloses a low-temperature synergistic biological agent, its preparation method, and its application. The core innovation lies in using a unique engineered Bacillus subtilis strain as the core functional carrier, and performing a ternary targeted compounding with polydeoxyribonucleotides (PDRN) and biostimulants to achieve a triple synergistic low-temperature resistance effect. The engineered Bacillus subtilis strain was deposited at the China General Microbiological Culture Collection Center (CGMCC) on March 11, 2026, with accession number CGMCC No. 37899. The chassis strain of Bacillus subtilis was deposited at the same center on March 3, 2026, with accession number CGMCC No. 37834. The modification strategy involves knocking out the α-subunit gene of acetoin dehydrogenase and the phosphoacetyltransferase gene from the genome of Bacillus subtilis CGMCC No. 37834, and expressing the acetyllactate synthase gene and the α-acetyllactate decarboxylase gene.

This invention relates to the fields of molecular biology and forensic identification, specifically to a method for bird species identification based on multi-gene co-amplification and nanopore sequencing. The method involves extracting genomic DNA from avian biological samples; using the extracted DNA as a template, amplification is performed using four independent PCR primer pools that specifically target the avian mitochondrial cytochrome C oxidase subunit I gene, cytochrome B gene, 12S rRNA gene, and 16S rRNA gene; after purification of the amplification products, a nanopore sequencing library is constructed and sequenced; finally, bioinformatics analysis, including read length clustering, draft consensus sequence generation, and polishing, is performed on the raw sequencing data to obtain consensus sequences for each target gene. Species identification is then completed by comparing the sequence with a avian sequence database. This method effectively solves the problem that existing technologies cannot simultaneously meet the practical needs of large-scale, rapid, and high-success-rate identification of avian biological samples.

Provided in the present invention are an siRNA inhibiting inhibin subunit βE (INHBE) gene expression and a conjugate thereof. The siRNA comprises a sense strand and an antisense strand. The antisense strand comprises at least 17 consecutive nucleotides that differ from nucleotide sequences as set forth in SEQ ID NO: 2 to SEQ ID NO: 277 by no more than 4 nucleotides, and has a length of 17-30 nucleotides. The sense strand has a length of 17-30 nucleotides, and is at least partially complementary to the antisense strand. The siRNA, siRNA conjugate and pharmaceutical composition provided by the present invention have good stability, INHBE gene inhibitory activity, cytotoxicity and immunostimulatory activity.

The invention discloses a molecular marker and a primer group for detecting high-molecular-weight glutenin subunits of wheat and application of the molecular marker and the primer group, and belongs to the technical field of molecular marker-assisted breeding. The nucleotide sequence of the molecular marker is as shown in SEQ ID NO.3, and T / A mutation exists at the 21st base of the molecular marker; the wheat high-molecular-weight glutenin subunit of which the mutation site is T is Ax1, and the wheat high-molecular-weight glutenin subunit of which the mutation site is A is Ax2 *. The specific KASP molecular marker is developed on the basis of variation sites of Ax1 and Ax2 * subunit gene coding regions in a wheat genome, the Ax1 and Ax2 * subunit types of the wheat high-molecular-weight glutenin can be detected by utilizing the molecular marker, the identification result is accurate and reliable, the repeatability is good, the identification process of the high-molecular-weight glutenin subunit in wheat offspring is greatly simplified, and the application prospect is wide. And the identification efficiency and accuracy are improved.

The present disclosure provides human inhibin subunit beta E (INHBE) gene-targeting double stranded oligonucleotides, compositions, and methods of using the same, either alone or in combination with additional therapeutics, for preventing and / or treating various INHBE-related disorders, including maintenance of weight loss achieved. In some embodiments, the provided double stranded oligonucleotides comprise certain chemistry modifications, e.g., stereospecific internucleotidic linkage modifications, and have unexpected advantageous properties.

The invention relates to the technical field of crop breeding, and particularly discloses a wheat translocation chromosome and a molecular marker and application thereof, and the translocation chromosome comprises a 1AS. 1AL-1DLDx5 + Dy10 translocation chromosome formed by replacing a 475.8-598.6 Mb segment of a long arm end of a 1A chromosome with a 376.6-498.6 Mb segment of a wheat 1D chromosome long arm end. According to the invention, a 1AS.1AL-1DLDx5 + Dy10 translocation chromosome containing a Dx5 + Dy10 high-quality high-molecular-weight glutenin subunit gene is created, and a matched molecular marker is developed, so that the problems that in existing wheat breeding, excellent genes are lacked, specific translocation line identification depends on a time-consuming and labor-consuming cytological method, and high-throughput application is difficult are solved; according to the method, a 1AS.1 1AL-1DLDx5 + Dy10 translocation chromosome carrier and a non-carrier are rapidly and accurately distinguished, traditional cytological identification is replaced, molecular marker-assisted breeding is supported, and the breeding process of a new variety of high-quality wheat is accelerated.

A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mIl2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG / Il2rg KO / hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g., S. typhi or M. tuberculosis is described. A mouse that models a human pathogen infection that is poorly modeled in mice is described, e.g., a mouse that models a human mycobacterial infection, wherein the mouse develops one or more granulomas comprising human immune cells. A mouse that comprises a human hematopoietic malignancy that originates from an early human hematopoietic cells is described, e.g., a myeloid leukemia or a myeloproliferative neoplasia.

The present invention relates to a therapeutic compound, a novel RNA interference (RNAi) agent, that reduces the expression of the voltage-gated sodium channel α subunit 10 (SCN10A) gene, which encodes Nav1.8 or a subunit of the Nav1.8 sodium channel. Such RNAi agents reduce the level of intact Nav1.8 sodium channels and are useful in the treatment of diseases in which the regulation of SCN10A expression and function is involved, such as chronic pain.

The application belongs to the technical field of biological identification, and provides a molecular identification reagent for Olotanussus and Endothrips spp., which comprises a pair of primers for detecting COI gene sequence of the thrips: olotCOI-F: 5-ATATTAGGAGCTCCAGATATAGC-3; olotCOI-R: 5-GGGTGACCAAAAAATCAAAATAA-3; and further comprises a BclI enzyme cutting site designed in the sequence of the Olotanussus. According to the sequence difference of the mitochondrial cytochrome C oxidase subunit I gene between the thrips species, a species-specific variation site of the Olotanussus and the Endothrips spp. is found, a molecular identification system for the thrips species is established, and finally the rapid, accurate and efficient identification of the thrips and the closely related species is realized.

The present invention provides compositions and methods useful for reducing sodium voltage-gated channel alpha subunit 9 (SCN9A) gene expression and treating SCN9A-associated diseases and disorders. The present invention provides SCN9A dsRNA agents, SCN9A antisense polynucleotide agents, compositions comprising SCN9A dsRNA agents, and compositions comprising SCN9A antisense polynucleotide agents useful for reducing SCN9A expression in cells and subjects.

The application belongs to the technical field of plant genetic engineering, and particularly relates to an extension factor subunit OsELP4 gene for regulating rice blast resistance and application. An extension factor subunit OsELP4 gene induced by Magnaporthe oryzae is screened, the nucleotide sequence of the gene is shown as SEQ ID NO:1, and the protein sequence coded by the gene is shown as SEQ ID NO:2. By using Agrobacterium-mediated transformation, an OsELP4 overexpression transgenic line and a CRISPR / Cas9 mutant line are obtained. It is found by inoculating and identifying the transgenic materials with rice blast that the OsELP4 overexpression line has enhanced resistance to rice blast, and the mutant line is more susceptible to rice blast, which indicates that OsELP4 is a positive regulation factor for rice resistance to rice blast. OsELP4 plays a positive regulation role in rice resistance to rice blast, and overexpression of the gene can significantly improve the resistance of rice to rice blast.

The application belongs to the technical field of biology and particularly relates to a poplar anti-osmotic stress gene and application thereof. The poplar anti-osmotic stress gene is a NATB CATALYTIC SUBUNIT gene, the nucleotide sequence of which is shown as SEQ ID No. 1. Inhibition of the expression of the NATB CATALYTIC SUBUNIT gene in a plant body can effectively improve the net photosynthetic rate of the plant under osmotic stress conditions and promote root system development. Therefore, the NATB CATALYTIC SUBUNIT gene can be used for cultivating new varieties with high yield, high quality and anti-osmosis, and has great application value for genetic improvement of comprehensive stress resistance of forest trees and provides a new idea for creating new poplar anti-osmosis germplasm.

The invention provides an engineering bacterium for producing D-pantothenic acid as well as a construction method and application of the engineering bacterium. The engineering bacterium expresses an acetolactate synthase large subunit gene ilv2, an acetolactate synthase small subunit gene ilv6, a keto acid reductoisomerase gene ilvC, a dihydroxy acid dehydratase gene ilvD, a hydroxymethyltransferase gene ecm31, a keto pantoic acid reductase gene panE, an L-aspartic acid decarboxylase gene panD and a pantothenic acid synthase gene panC. According to the method, mitochondria is selected as a targeting compartment, and modular combination optimization approach positioning is adopted, so that the yield of D-pantothenic acid is greatly increased, compared with the yield of an original strain without spatial tissue optimization, the yield is increased by more than one time, the metabolic flux bottleneck in a traditional cytoplasm synthesis mode is broken through, and efficient synthesis of D-pantothenic acid is realized.

The application belongs to the technical field of genetic engineering, and discloses a method for improving tryptophan synthetase activity by constructing a nucleic acid scaffold, wherein a fusion tag dCE is fused to a tryptophan synthetase beta subunit gene, the base sequence of the tryptophan synthetase gene is SEQ ID NO:1, the base sequence of the dCE gene is SEQ ID NO:2-SEQ ID NO:5, and the tryptophan synthetase gene is derived from Escherichia coli. The fusion tag dCE is fused to the tryptophan synthetase gene of the Escherichia coli, and the results of heterologous expression with and without the fusion tag are compared. The fusion tag dCE has a soluble expression promoting effect on the protein. The soluble expression promoting effect of the tag ultimately obtains an engineered enzyme capable of catalyzing the substrate L-Ser, and forms a nucleic acid scaffold to improve the catalytic activity of the enzyme, thereby providing a new enzyme for the industrial production of L-Trp and a new way for the heterologous expression of L-Trp.

According to one aspect of the present invention, this method for detecting Fusobacterium nucleatum in a sample involves a step for subjecting a DNA derived from a sample to nucleic acid amplification reaction using a primer set specific to a citrate lyase beta subunit gene of Fusobacterium nucleatum. According to said method, F. nucleatum can be specifically detected. According to another aspect of the present invention, this method for detecting Fusobacterium nucleatum nucleatum in a sample involves a step for subjecting a DNA derived from a sample to nucleic acid amplification reaction using a primer set specific to a dicarboxylate / amino acid: cation cotransporter gene of Fusobacterium nucleatum nucleatum. According to said method, F. nucleatum nucleatum can be specifically detected.

The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents such as siRNAs, able to Inhibin Subunit Beta E (INHBE) gene expression. Also disclosed are pharmaceutical compositions that include INHBE RNAi agents and methods of use thereof. The INHBE RNAi agents disclosed herein may be conjugated to targeting ligands to facilitate the delivery to cells, including to hepatocytes. Delivery of the INHBE RNAi agents in vivo provides for inhibition of INHBE gene expression. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms mediated in part by INHBE gene expression, such as obesity, diabetes, liver inflammation, dyslipidemia, or metabolic disease.

The invention discloses a Glu-1Ey gene for regulating and controlling wheat protein content, a protein and application of the Glu-1Ey gene. The nucleotide sequence of the Glu-1Ey gene is shown as SEQ ID No. 1. According to the invention, an overexpression vector for transforming the agropyron elongatum Glu-1Ey gene is successfully constructed by using a gene overexpression technology, and a strain for overexpressing the Glu-1Ey gene is obtained by using an agrobacterium-mediated wheat immature embryo genetic transformation method. The protein content analysis of transgenic wheat proves that the high-molecular-weight glutelin y-type subunit gene Glu-1Ey of elytrigia elongata can improve the protein content and glutelin content of wheat. The technical scheme provided by the invention has important significance for obtaining high-quality wheat new germplasm by utilizing the high-molecular-weight glutelin y-type subunit gene Glu-1Ey of elytrigia elongata.

The invention discloses an aspergillus vacuole proton pump subunit AnVma1 gene and application thereof. The amino acid sequence of the gene is as shown in SEQ ID NO. 1. The aspergillus is subjected to genetic manipulation to increase or enhance the activity of a specific gene, so that the secretion ability of glucoamylase and other proteins participating in starch hydrolysis can be improved. In a specific experiment, a recombinant strain with high-level expression of the gene is obtained by utilizing an overexpressed aspergillus niger gene AnVma1, the production level of amylolytic enzyme can be remarkably improved by the recombinant strain, the protein secretion level after culture in a 5L fermentation tank is improved by about 44% compared with that of an original strain, the activity of saccharifying enzyme is improved by about 30% compared with that of the original strain, and the yield of the amylolytic enzyme is improved by about 30% compared with that of the original strain. And the method has a relatively high application value.

The application provides an siRNA targeting INHBE gene expression and a conjugate and use thereof. The application belongs to the technical field of biological medicines. Specifically, the application provides an siRNA for inhibiting inhibin subunit beta E (INHBE) gene expression and a conjugate thereof, which comprises a sense strand and an antisense strand. The antisense strand comprises at least 17 continuous nucleotides which differ by no more than 4 nucleotides from the nucleotide sequences shown in SEQ ID NO: 299~SEQ ID NO: 595, SEQ ID NO: 751~SEQ ID NO: 904, and SEQ ID NO: 909~SEQ ID NO: 911, and the length of the antisense strand is 17~30 nucleotides; the length of the sense strand is 17~30 nucleotides, and the sense strand is at least partially complementary to the antisense strand. The siRNA, the siRNA conjugate and the pharmaceutical composition provided by the application have good stability, excellent INHBE gene inhibition activity, satisfactory cytotoxicity and immunostimulation.

The invention provides siRNA (small interfering Ribonucleic Acid) for targeting INHBE gene expression as well as a conjugate and application of the siRNA. The invention belongs to the technical field of biological medicine. Specifically, the invention provides a siRNA (small interfering Ribonucleic Acid) for inhibiting expression of an statin subunit beta E (INHBE) gene and a conjugate thereof, and the siRNA comprises a positive-sense strand and an antisense strand. The antisense strand comprises at least 17 contiguous nucleotides which are different from the nucleotide sequences as shown in SEQ ID NO: 299 to SEQ ID NO: 595, SEQ ID NO: 751 to SEQ ID NO: 904 and SEQ ID NO: 909 to SEQ ID NO: 911 by not more than 4 nucleotides, and the length of the antisense strand is 17 to 30 nucleotides; the length of the positive-sense strand is 17-30 nucleotides, and the positive-sense strand is at least partially complementary to the antisense strand. The siRNA, the siRNA conjugate and the pharmaceutical composition provided by the invention have good stability, excellent INHBE gene inhibition activity, and satisfactory cytotoxicity and immunostimulation.